Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

Cancer

Volumn 115, Issue 15, 2009, Pages 3501-3511

  Affronti, Mary Lou ^a   Heery, Christopher R ^a   Herndon II, James E ^a   Rich, Jeremy N ^a   Reardon, David A ^a   Desjardins, Annick ^a   Vredenburgh, James J ^a   Friedman, Allan H ^a   Bigner, Darell D ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BCNU wafer; Glioma; Radiotherapy; Surgery; Temozolomide

Indexed keywords

CARMUSTINE; IRINOTECAN; LOMUSTINE; TAMOXIFEN; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BRAIN EDEMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENINGOCELE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PSEUDOMENINGOCELE; RADIATION SICKNESS; SEIZURE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 68149181745     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24398     Document Type: Article

References (19)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
3. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Affronti ML, Rich JR, Day JM, et al. Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients [abstract]. J Clin Oncol. 2007;25(suppl):92. Abstract 33458.
6. Curran W. Recursive partitioning analysis of prognostic factors in 3 radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
7. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563-2569.
8. La Rocca RV, Hodes J, Villanuera TW, et al. A phase II study of radiation with concomitant and then sequential temozolomide (temozolomide) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion [abstract]. Neuro Oncol. 2006;8:445. Abstract TA28:445.
9. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
10. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996;56:783-788.
11. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
12. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871-1874.
13. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
14. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol. 1994;21:135-140.
15. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310-3315.
16. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024.
17. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24:1253-1265.
18. Raizer JJ, Malkin MG, Kleber M, et al. Phase 1 study of 28-day low dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro Oncol. 2004;6:247-252.
19. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of BCNU wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol. 2001;3:246-250.